Breakthrough Therapeutics for CLL and Other B-Cell Malignancies: Focus on BTK Inhibitors

Breakthrough Therapeutics for CLL and Other B-Cell Malignancies: Focus on BTK Inhibitors

Friday, December 9, 2022 in New Orleans, LA
Dinner -- Hyatt Regency New Orleans, 7:00 PM CT
Elite B

Agenda

  • Review of Current and Emerging BTK Inhibitors
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    • Includes Patient Cases and Panel Discussion on Therapy Selection and Adverse Event Management
  • Mantle Cell Lymphoma
    • Includes Patient Cases and Panel Discussion on Therapy Selection and Adverse Event Management
  • Final Thoughts and Audience Question and Answer Session

Faculty

Program Director
Jeff Sharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Faculty
Ian W. Flinn, MD, PhD

Director, Lymphoma Research 
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Faculty
Susan M. O’Brien, MD

Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center
Medical Director, Sue & Ralph Stern Center for Clinical Trials & Research
Professor, Division of Hematology/Oncology
School of Medicine
University of California, Irvine
Orange, California

Goal Statement
The goal of this activity is to improve the knowledge, competence, and confidence of learners to apply practice-changing clinical data and expert recommendations in order to optimize the use of current and emerging therapeutic strategies with BTKi in the care of their patients with CLL/SLL and MCL.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with CLL/SLL or MCL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Compare first-generation and next-generation BTK inhibitors in terms of molecular characteristics, binding, targeted selectivity, approved indications, dosing, safety profile, and efficacy
  • Plan BTK inhibitor–based therapeutic strategies for treatment-naive patients with CLL/SLL or MCL, taking into consideration guidelines, expert recommendation, and recent practice-changing clinical trial results
  • Select optimal therapy in R/R CLL/SLL or MCL following progression on or intolerance of first-line and subsequent therapies
  • Manage toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, and treatment continuation and to maximize patient survival and quality of life
  • Identify patients eligible for ongoing clinical trials evaluating currently available and emerging BTK inhibitors and BTK inhibitor–based combinations

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.